Lipid profiles in untreated patients with dermatomyositis

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 2, 2013, Pages 175-179

  Wang, H ^a,b   Tang, J ^a   Chen, X ^b   Li, F ^b   Luo, J ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DERMATOMYOSITIS; DIAGNOSTIC TEST ACCURACY STUDY; DYSLIPOPROTEINEMIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CASE-CONTROL STUDIES; DERMATOMYOSITIS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84872682005     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04437.x     Document Type: Article

References (33)

1. Dalakas MC, Hohlfeld R,. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-982.
2. Sultan SM, Ioannou Y, Moss K, Isenberg DA,. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002; 41: 22-26.
3. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G,. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004; 83: 35-42.
4. Bohan A, Peter JB, Bowman RL, Bowman RL, Pearson CM,. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977; 56: 255-286.
5. de Carvalho JF, Bonfá E, Borba EF,. Systemic lupus erythematosus and "lupus dyslipoproteinemia". Autoimmun Rev 2008; 7: 246-250.
6. Steiner G, Urowitz MB,. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009; 38: 372-381.
7. Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR,. Serum lipid levels in Sjogren's syndrome. Rheumatology 2006; 45: 481-484.
8. Borba EF, Carvalho JF, Bonfá E,. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 2006; 13: 203-208.
9. Reiss AB,. Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11: 255-260.
10. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1608-1612.
11. Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC,. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1384-1396.
12. Bohan A, Peter JB,. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-347.
13. Sherer Y, Shoenfeld Y,. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2: 99-106.
14. Frostegård J,. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005; 25: 1776-1785.
15. Eimer MJ, Brickman WJ, Seshadri R, et al. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. J Pediatr 2011; 159: 795-801.
16. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006; 8: R82.
17. Choi HK, Seeger JD,. Lipid profiles among US elderly with untreated rheumatoid arthritis-the Third National Health and Nutrition Examination Survey. J Rheumatol 2005; 32: 2311-2316.
18. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1701-1704.
19. Dursunoglu D, Evrengul H, Polat B, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-245.
20. Love PE, Santoro SA,. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders; prevalence and clinical significance. Ann Intern Med 1990; 112: 682-698.
21. Kodera M, Hayakawa I, Komura K, et al. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations. J Rheumatol 2005; 32: 629-636.
22. Delgado AJ, Kumar S, Isenberg DA,. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2003; 42: 893-899.
23. Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC,. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1033-1040.
24. Borba EF, Bonfa E,. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533-539.
25. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU,. A phase I trial of intravenously administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6: 1328-1334.
26. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegård J,. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533-2540.
27. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-305.
28. Yeh ETH,. CRP as a mediator of disease. Circulation 2004; 109: 11-14.
29. Asanuma Y, Chung CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33: 539-545.
30. de Carvalho JF, Bonfá E, Bezerra MC, Pereira RM,. High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis. Clin Rheumatol 2009; 28: 801-805.
31. de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfá E,. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004; 50: 3610-3615.
32. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR,. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93: 198-200.
33. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.